Globus Medical Price to Free Cash Flow Ratio 2010-2022 | GMED

Historical price to free cash flow ratio values for Globus Medical (GMED) since 2010. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
Globus Medical Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2023-01-27 75.86 65.24
2022-09-30 59.57 $1.16 51.23
2022-06-30 56.14 $1.51 37.13
2022-03-31 73.78 $1.87 39.51
2021-12-31 72.20 $2.12 34.10
2021-09-30 76.62 $2.19 35.06
2021-06-30 77.53 $1.97 39.31
2021-03-31 61.67 $1.63 37.83
2020-12-31 65.22 $1.34 48.73
2020-09-30 49.52 $1.07 46.50
2020-06-30 47.71 $1.15 41.64
2020-03-31 42.53 $-0.07 0.00
2019-12-31 58.88 $0.02 2700.92
2019-09-30 51.12 $0.01 0.00
2019-06-30 42.30 $-0.21 0.00
2018-12-31 43.28 $1.25 34.54
2018-09-30 56.76 $1.96 28.92
2018-06-30 50.46 $1.71 29.58
2018-03-31 49.82 $1.72 28.92
2017-12-31 41.10 $1.45 28.35
2019-03-31 49.41 $0.89 55.57
2017-09-30 29.72 $0.91 32.78
2017-06-30 33.15 $1.06 31.40
2017-03-31 29.62 $1.06 27.93
2016-12-31 24.81 $1.11 22.38
2016-09-30 22.57 $1.32 17.16
2016-06-30 23.83 $1.13 21.00
2016-03-31 23.75 $0.96 24.84
2015-12-31 27.82 $0.76 36.49
2015-09-30 20.66 $0.35 58.26
2015-06-30 25.67 $0.50 51.43
2015-03-31 25.24 $0.61 41.12
2014-12-31 23.77 $0.57 41.69
2014-09-30 19.67 $0.94 20.98
2014-06-30 23.92 $0.90 26.69
2014-03-31 26.59 $0.86 30.90
2013-12-31 20.18 $0.74 27.24
2013-09-30 17.46 $0.64 27.47
2013-06-30 16.86 $0.71 23.60
Sector Industry Market Cap Revenue
Medical Medical Instruments Manufacturing $7.506B $0.958B
Globus Medical, Inc. is a medical device company that develops and commercializes healthcare solutions for patients with musculoskeletal disorders. The company currently has its sales operations distributed across counties world wide. Its Musculoskeletal Solutions consist primarily of implantable devices, biologics, accessories, and unique surgical instruments, used in an expansive range of spinal, orthopedic and neurosurgical procedures. The spine products address the vast majority of conditions affecting the spine including degenerative conditions, deformity, tumors and trauma. Enabling Technologies are designed to enhance a surgeon's capabilities and streamline the complicated surgical procedures to be safer, less invasive, accurate and more reproducible to improve patient care and reduce radiation exposure for both patient and caregiver. The technology contains imaging, navigation and robotic assisted surgery solutions. It acquired all assets of StelKast, Inc. and Finnish engineering company Synoste Oy.
Stock Name Country Market Cap PE Ratio
Thermo Fisher Scientific (TMO) United States $226.442B 23.68
Edwards Lifesciences (EW) United States $48.354B 33.28
Alcon (ALC) Switzerland $36.722B 31.62
STERIS (STE) Ireland $20.456B 25.46
Teleflex (TFX) United States $11.305B 18.34
Fresenius Medical Care AG KGaA (FMS) Germany $10.584B 10.62
Penumbra (PEN) United States $9.289B 2223.46
Integer Holdings (ITGR) United States $2.380B 19.11
Glaukos (GKOS) United States $2.298B 0.00
AVANOS MEDICAL, INC (AVNS) United States $1.402B 19.97
Paragon 28 (FNA) United States $1.303B 0.00
Nevro (NVRO) United States $1.291B 0.00
Artivion (AORT) United States $0.505B 0.00